Jump to content

Orelabrutinib

From Wikipedia, the free encyclopedia

Orelabrutinib
Clinical data
Trade names宜诺凯 (China), Hibruka (Singapore)
Other namesICP-022; ICP022
Drug classBruton's tyrosine kinase inhibitor
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 2-(4-Phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC26H25N3O3
Molar mass427.504 g·mol−1
3D model (JSmol)
  • C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4
  • InChI=1S/C26H25N3O3/c1-2-24(30)29-16-14-18(15-17-29)23-13-12-22(26(27)31)25(28-23)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-13,18H,1,14-17H2,(H2,27,31)
  • Key:MZPVEMOYADUARK-UHFFFAOYSA-N

Orelabrutinib is a small molecule inhibitor of Bruton's tyrosine kinase used for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and marginal zone lymphoma.[1][2][3]

In China, it is approved for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), who have received at least one treatment in the past.[1]

In Singapore, it is approved for adult patients with relapsed or refractory marginal zone lymphoma (R/R MZL).[3]

Orelabrutinib is an inhibitor of Bruton's tyrosine kinase, thus being a BTK inhibitor.[2]

Society and culture

[edit]
[edit]

Orelabrutinib was approved for medical use in China in December 2020.[1]

Orelabrutinib was approved for medical use in Singapore in September 2025.[3]

Names

[edit]

Orelabrutinib is the international nonproprietary name.

Orelabrutinib is sold under the brand names 宜诺凯 in China, and Hibruka in Singapore.[1][3]

References

[edit]
  1. 1 2 3 4 Dhillon S (March 2021). "Orelabrutinib: First Approval". Drugs. 81 (4): 503–507. doi:10.1007/s40265-021-01482-5. PMID 33704654.
  2. 1 2 Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, et al. (August 2023). "Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study". Blood Advances. 7 (16): 4349–4357. doi:10.1182/bloodadvances.2022009168. PMC 10432605. PMID 37078706.
  3. 1 2 3 4 "InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore | INNOCARE". www.innocarepharma.com. Archived from the original on 2026-06-16. Retrieved 2026-10-22.